Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $67,455 | $59,952 | $49,324 | $73,694 |
| % Growth | 12.5% | 21.5% | -33.1% | – |
| Cost of Goods Sold | $1,408 | $56,664 | $49,741 | $45,543 |
| Gross Profit | $66,047 | $3,288 | -$417 | $28,151 |
| % Margin | 97.9% | 5.5% | -0.8% | 38.2% |
| R&D Expenses | $75,174 | $79,363 | $76,879 | $72,224 |
| G&A Expenses | $0 | $0 | $10,578 | $0 |
| SG&A Expenses | $34,555 | $37,699 | $43,925 | $42,503 |
| Sales & Mktg Exp. | $0 | $0 | $33,347 | $0 |
| Other Operating Expenses | $51,219 | $0 | $0 | $0 |
| Operating Expenses | $160,948 | $117,062 | $120,804 | $114,727 |
| Operating Income | -$94,901 | -$113,774 | -$121,221 | -$86,576 |
| % Margin | -140.7% | -189.8% | -245.8% | -117.5% |
| Other Income/Exp. Net | $1,243 | $4,104 | $3,220 | $9,575 |
| Pre-Tax Income | -$93,658 | -$109,670 | -$118,001 | -$77,001 |
| Tax Expense | -$2,405 | $1,988 | -$1,838 | $1,558 |
| Net Income | -$91,253 | -$111,658 | -$116,163 | -$78,559 |
| % Margin | -135.3% | -186.2% | -235.5% | -106.6% |
| EPS | -0.25 | -0.33 | -0.36 | -0.26 |
| % Growth | 24.2% | 8.3% | -38.5% | – |
| EPS Diluted | -0.25 | -0.33 | -0.36 | -0.26 |
| Weighted Avg Shares Out | 364,037 | 334,511 | 322,868 | 304,890 |
| Weighted Avg Shares Out Dil | 364,037 | 334,511 | 322,868 | 304,890 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $4,104 | $3,220 | $9,575 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $9,007 | $11,938 | $11,065 | $11,687 |
| EBITDA | -$84,651 | -$101,836 | -$106,936 | -$74,889 |
| % Margin | -125.5% | -169.9% | -216.8% | -101.6% |